For instance, in the various clinical trials of RA patients with anti-TNF agents, ACR20 response rates are generally higher in methotrexate-naïve subjects than in methotrexate-experienced or TNF inhibitor-experienced subjects (Smolen and Aletaha, 2015). This evidence concerns the gene TNF and rheumatoid arthritis.